Please assess the completion status of the following clinical trial:

Trial Title: The Post-Marketing Safety and Immunogenicity Research of Speeda® Rabies Vaccine for Human Use

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Parent/legal acceptable representatives of children or the adult participants are willing and able to understand the protocol requirements and provide informed consent signed~* Participant is considered to be in good health including the body and mental status on the basis of reported medical history and limited physical examination and live in local ≥ 12 months~* Participant body temperature ≤ 37.0℃~* Participant without preventive inoculation of rabies vaccine(only limited in immunogenicity subgroup)~Exclusion Criteria:~* Three-level exposure~* Known allergy to any constituent of the vaccine~* Reported the history of allergies, convulsions, epilepsy, mental illness and brain disease and clear serious systemic reaction~* Known bleeding disorder or suspected impairment of immunologic function, or receipt of immunosuppressive therapy or immunoglobulin since birth~* Participation in any other interventional clinical trial~* An acute illness with or without fever (temperature \> 37.0℃) in the latest week preceding enrollment in the trial~* Inoculated other vaccines, immunoglobulin or investigational drugs within 4 weeks prior to participation in the study~* Reported clearly the infection of the upper respiratory tract with 6 months Clinical Manifestation of Metabolic, blood system, lungs, heart, the gastrointestinal tract, nervous system, kidneys, urinary system, endocrine, liver disease or malignant tumor~* Any condition which, in the opinion of the investigator, would pose a health risk to the subject or interfere with the vaccine

- Gender: ALL
- Minimum Age: None
- Maximum Age: None
- Healthy Volunteers: t

Study Arms:
- Zagreb2-1-1 (Type: EXPERIMENTAL): Injection on day 0、7、21
- Essen (Type: ACTIVE_COMPARATOR): Injection on day 0、3、7、14、28

Based on this trial design, predict the completion outcome and termination type (if applicable).